NATICK, Mass.--(BUSINESS WIRE)--AffyImmune, a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, presented preclinical data on ...

A study led by Chinese radiologists at Peking University in Beijing has shown that positron emission tomography (PET) imaging of intercellular adhesion molecule-1 (ICAM-1) expression is a predictor ...

Presentation characteristics, risk profiles and long-term outcomes in a public health system, minority patient population with diffuse large B-cell lymphoma No significant financial relationships to ...

First report to show link between GDF-15 and LFA-1/ICAM-1 cell adhesion axis in cancer, resulting in impaired infiltration of T cells into the tumor microenvironment First report to show link between ...

Identification of biomarkers for TAS-102 efficacy in metastatic colorectal cancer patients based on preclinical analysis and clinical validation.

This foundational research describes a mechanistic link between tumor-produced Growth Differentiation Factor-15 (GDF-15) and the LFA-1/ICAM-1 cell adhesion axis. The interaction between LFA-1/ICAM-1 ...

A new chimeric antigen receptor (CAR) T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types of ...